Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib and Immune Checkpoint Inhibitors in Advanced Solid Tumors
NCT04317105Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2020
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of copanlisib in solid tumor (2 arms), sponsored by National Cancer Institute. Primary endpoint: Dose Limiting Toxicities at 8 weeks. Started Jul 2020; status: active, not recruiting.
02
Drugs
copanlisib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04317105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04317105.